SCYNEXIS today announced that the Company will participate in two upcoming investor conferences.
JERSEY CITY, N.J., Nov. 28, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:
The Global Mizuho Investor Conference (MIC) NY at the Lotte New York Palace Hotel on Monday, December 4, 2017.
The Guggenheim Securities 5th Annual Boston Healthcare Conference at the InterContinental Boston on Wednesday, December 13, 2017.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT:
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
SOURCE SCYNEXIS, Inc.
